Such structural insights open avenues for a novel drug design that may play a significant role in modulating the cGAS–STING signaling-mediated autophagy axis which may be regulated by FOXO1 and FOXO3a in NSCLC. The gene discussed is FOXO1; the disease is non-small cell lung carcinoma.